114 Per Cent Returns: Multibagger Pharma Company Reports 81 Per Cent PAT Growth; Sales Up 9 Per Cent
114 Per Cent Returns: Multibagger Pharma Company Reports 81 Per Cent PAT Growth; Sales Up 9 Per Cent

114 Per Cent Returns: Multibagger Pharma Company Reports 81 Per Cent PAT Growth; Sales Up 9 Per Cent

The company's net profit surged 81 per cent year-on-year (YoY) to Rs 276.4 crore, compared to Rs 152.9 crore in Q3 FY24.

Manoj Reddy Sama Article rating: 3.8

Revenue grew by 9 per cent YoY to Rs 2,245.4 crore, up from Rs 2,052.9 crore in the corresponding quarter last year.

Pharma Major Shares Rebound from Lows; Firm Reports 39.5 per cent Profit Growth
Pharma Major Shares Rebound from Lows; Firm Reports 39.5 per cent Profit Growth

Pharma Major Shares Rebound from Lows; Firm Reports 39.5 per cent Profit Growth

The company reported a net income of Rs 8,552 crore, marking a 39.5 per cent YoY growth. Total sales increased 10.6 per cent YoY to Rs 56,186 crore from Rs 50,799 crore in Q3 FY24

Abhishek Wani Article rating: 5.0

The company reported a net income of Rs 8,552 crore, marking a 39.5 per cent YoY growth. Total sales increased 10.6 per cent YoY to Rs 56,186 crore from Rs 50,799 crore in Q3 FY24

This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here
This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here

This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here

The Board of Directors approved the issuance of commercial papers worth Rs 570 crore on a private placement basis

Abhishek Wani Article rating: 3.3

The Board of Directors approved the issuance of commercial papers worth Rs 570 crore on a private placement basis

CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why
CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why

CDMO Company's Shares Surge Over 12 Per Cent in Two Trading Sessions; Here’s Why

The company's shares surged 10 per cent to hit the upper circuit at Rs 668.10 on the BSE. This marked the second consecutive session of gains for the stock

Manoj Reddy Sama Article rating: 5.0

Under the agreement, Akums will receive an upfront payment of EUR 100 million (Rs 880 crore) to fund product development and secure European regulatory approvals for its oral liquid manufacturing facility.

RSS
12345

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR